US FDA grants full approval to remdesivir for the treatment of Covid-19

It is approved for the treatment of COVID-19 requiring hospitalisation in adults and paediatrics ≥12 years and ≥40kg. Its use in younger patients weighing at least 3.5kg is covered under the amended Emergency Use Authorisation and trials in this population are ongoing.

Source:

US Food and Drug Administration